Sequana Medical to attend 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright BIOCONNECT Virtual Conference
December 17, 2021 01:00 ET
|
Sequana Medical NV
CEO Ian Crosbie to participate in a panel discussion on “MedTech and digital tools: What is the Mindset for 2022?” Ghent, Belgium – 17 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA,...
Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion
December 07, 2021 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION7 December 2021, 07:00 am CET Interim data from six patients indicate that alfapump DSR therapy can: safely, effectively and rapidly eliminate...
Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study
December 06, 2021 01:00 ET
|
Sequana Medical NV
Positive interim analysis reported in July 2021Reporting of primary endpoint planned for Q4 2022 Ghent, Belgium – 6 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or...
Sequana Medical to present at Jefferies London Healthcare Conference
November 09, 2021 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 9 November 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites...
Sequana Medical receives MDSAP certification and expands its Quality Management System towards North America
November 03, 2021 02:00 ET
|
Sequana Medical NV
Ghent, Belgium – 3 November 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...
Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
October 04, 2021 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION - INSIDE INFORMATION4 October 2021, 07:00 CET Completion of patient enrolment expected before end of year Primary endpoint read-out due in Q4 202259 patients...
Sequana Medical to present at 8th Annual HealthTech Investment Forum
September 28, 2021 01:00 ET
|
Sequana Medical NV
Participating in Next Generation Medtech & Device Panel on October 5th, 2021 Ghent, Belgium – 28 September 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in...
Sequana Medical announces H1 2021 results and provides business update
September 02, 2021 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION2 September 2021, 07:00 CET alfapump® – Positive results from second interim analysis of POSEIDON pivotal study; awaiting FDA approval on...
Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors
August 31, 2021 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 31 August 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites...
Sequana Medical Notice of 2021 Half Year Results and Business Update
August 26, 2021 01:00 ET
|
Sequana Medical NV
Ghent, BELGIUM – 26 August 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites...